Most Read Articles
11 Aug 2017
Magnetoencephalography (MEG) can detect functional network alterations accompanied by amyloid-β (Aβ) deposition in cognitively normal (CN) elderly adults before anatomical changes can be observed, a new study shows.
2 days ago
At least one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) has high individual vaccine effectiveness (VE) in preventing invasive pneumococcal disease (IPD) in a paediatric population with suboptimal vaccination coverage, a new study has shown.
09 Aug 2017
Longer sleep duration is positively associated with better metabolic profiles, a new study has shown. On the other hand, there is no direct correlation between sleep duration and dietary intake.
Jairia Dela Cruz, 4 days ago
Capecitabine appears to provide additional survival benefit in triple-negative breast cancer patients treated with standard chemotherapy, significantly improving disease-free survival and overall survival but potentially increasing adverse events consistent with the drug’s known toxicity profile, according to a meta-analysis.

CBT-fluoxetine combo therapy outperforms single treatment for hypochondriasis

06 Aug 2017

A recent study has shown the safety, efficacy and tolerance of fluoxetine for hypochondriasis. Moreover, joint treatment with both fluoxetine and cognitive behavioural therapy (CBT) confers a small incremental benefit over a single active treatment.

To determine whether joint treatment provides additional benefit, researchers randomized 195 patients with DSM-IV hypochondriasis to one of four treatments: placebo, CBT, fluoxetine, or joint treatment with fluoxetine and CBT. Analyses focused on hypochondriasis, adverse events, quality of life, functional status and other psychopathology.

At week 24, outcome was assessed among the intent-to-treat patients, with responders defined as having a ≥25-percent improvement over baseline on both the Whiteley Index and a modified version of the Yale-Brown Obsessive Compulsive Scale for hypochondriasis (H-YBOCS-M).

The Cochran-Armitage trend test assessed the hypothesized pattern of response: joint treatment > CBT or fluoxetine treatment > placebo treatment.

There was a statistically significant predicted pattern of response as shown by the following responder rates: joint treatment group, 47.2 percent; single active treatment group, 41.8 percent; and placebo group, 29.6 percent. There was no significant difference between responder rates for each active treatment and the rate for placebo.

Based on secondary analyses of the Whiteley Index as a continuous measure, fluoxetine was more effective at week 24 in reducing hypochondriasis and had a significantly faster rate of improvement over 24 weeks than placebo. Fluoxetine also led to significantly less anxiety and better quality of life compared with placebo.

Dropout rates were not different between groups. In addition, there was an even distribution of treatment-emergent adverse events.

According to researchers, “[b]ecause approximately 50 percent of patients did not respond to the study treatments, new or more intensive approaches are needed.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
11 Aug 2017
Magnetoencephalography (MEG) can detect functional network alterations accompanied by amyloid-β (Aβ) deposition in cognitively normal (CN) elderly adults before anatomical changes can be observed, a new study shows.
2 days ago
At least one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) has high individual vaccine effectiveness (VE) in preventing invasive pneumococcal disease (IPD) in a paediatric population with suboptimal vaccination coverage, a new study has shown.
09 Aug 2017
Longer sleep duration is positively associated with better metabolic profiles, a new study has shown. On the other hand, there is no direct correlation between sleep duration and dietary intake.
Jairia Dela Cruz, 4 days ago
Capecitabine appears to provide additional survival benefit in triple-negative breast cancer patients treated with standard chemotherapy, significantly improving disease-free survival and overall survival but potentially increasing adverse events consistent with the drug’s known toxicity profile, according to a meta-analysis.